357 related articles for article (PubMed ID: 20202729)
1. Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies.
Boyer O; Balzamo E; Charbit M; Biebuyck-Gougé N; Salomon R; Dragon-Durey MA; Frémeaux-Bacchi V; Niaudet P
Am J Kidney Dis; 2010 May; 55(5):923-7. PubMed ID: 20202729
[TBL] [Abstract][Full Text] [Related]
2. Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1/CFHR3 deficiency.
Lee BH; Kwak SH; Shin JI; Lee SH; Choi HJ; Kang HG; Ha IS; Lee JS; Dragon-Durey MA; Choi Y; Cheong HI
Pediatr Res; 2009 Sep; 66(3):336-40. PubMed ID: 19531976
[TBL] [Abstract][Full Text] [Related]
3. Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses.
Sana G; Dragon-Durey MA; Charbit M; Bouchireb K; Rousset-Rouvière C; Bérard E; Salomon R; Frémeaux-Bacchi V; Niaudet P; Boyer O
Pediatr Nephrol; 2014 Jan; 29(1):75-83. PubMed ID: 23868108
[TBL] [Abstract][Full Text] [Related]
4. The autoimmune disease DEAP-hemolytic uremic syndrome.
Skerka C; Zipfel PF; Müller D; Micklisch S; Riedl M; Zimmerhackl LB; Hofer J
Semin Thromb Hemost; 2010 Sep; 36(6):625-32. PubMed ID: 20865639
[TBL] [Abstract][Full Text] [Related]
5. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children.
Sinha A; Gulati A; Saini S; Blanc C; Gupta A; Gurjar BS; Saini H; Kotresh ST; Ali U; Bhatia D; Ohri A; Kumar M; Agarwal I; Gulati S; Anand K; Vijayakumar M; Sinha R; Sethi S; Salmona M; George A; Bal V; Singh G; Dinda AK; Hari P; Rath S; Dragon-Durey MA; Bagga A;
Kidney Int; 2014 May; 85(5):1151-60. PubMed ID: 24088957
[TBL] [Abstract][Full Text] [Related]
6. Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome.
Hofer J; Janecke AR; Zimmerhackl LB; Riedl M; Rosales A; Giner T; Cortina G; Haindl CJ; Petzelberger B; Pawlik M; Jeller V; Vester U; Gadner B; van Husen M; Moritz ML; Würzner R; Jungraithmayr T;
Clin J Am Soc Nephrol; 2013 Mar; 8(3):407-15. PubMed ID: 23243267
[TBL] [Abstract][Full Text] [Related]
7. Complement factor H deficiency and posttransplantation glomerulonephritis with isolated C3 deposits.
Boyer O; Noël LH; Balzamo E; Guest G; Biebuyck N; Charbit M; Salomon R; Frémeaux-Bacchi V; Niaudet P
Am J Kidney Dis; 2008 Apr; 51(4):671-7. PubMed ID: 18371543
[TBL] [Abstract][Full Text] [Related]
8. Anti-factor H autoantibody-associated hemolytic uremic syndrome: review of literature of the autoimmune form of HUS.
Dragon-Durey MA; Blanc C; Garnier A; Hofer J; Sethi SK; Zimmerhackl LB
Semin Thromb Hemost; 2010 Sep; 36(6):633-40. PubMed ID: 20865640
[TBL] [Abstract][Full Text] [Related]
9. Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome.
Strobel S; Hoyer PF; Mache CJ; Sulyok E; Liu WS; Richter H; Oppermann M; Zipfel PF; Józsi M
Nephrol Dial Transplant; 2010 Jan; 25(1):136-44. PubMed ID: 19666655
[TBL] [Abstract][Full Text] [Related]
10. Favorable four-yr outcome after renal transplantation in a patient with complement factor H antibody and CFHR1/CFHR3 gene mutation-associated HUS.
Grenda R; Jarmużek W; Rubik J; Prokurat S; Miklaszewska M; Drozdz D; Zachwieja K; Ardissino G; Hofer J
Pediatr Transplant; 2015 Sep; 19(6):E130-4. PubMed ID: 26087050
[TBL] [Abstract][Full Text] [Related]
11. Complement factor H, FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome.
Bernabéu-Herrero ME; Jiménez-Alcázar M; Anter J; Pinto S; Sánchez Chinchilla D; Garrido S; López-Trascasa M; Rodríguez de Córdoba S; Sánchez-Corral P
Mol Immunol; 2015 Oct; 67(2 Pt B):276-86. PubMed ID: 26163426
[TBL] [Abstract][Full Text] [Related]
12. Autoantibodies in haemolytic uraemic syndrome (HUS).
Skerka C; Józsi M; Zipfel PF; Dragon-Durey MA; Fremeaux-Bacchi V
Thromb Haemost; 2009 Feb; 101(2):227-32. PubMed ID: 19190803
[TBL] [Abstract][Full Text] [Related]
13. Effect of plasma exchange and immunosuppressive medications on antibody titers and outcome in anti-complement factor H antibody-associated hemolytic uremic syndrome.
Khandelwal P; Gupta A; Sinha A; Saini S; Hari P; Dragon Durey MA; Bagga A
Pediatr Nephrol; 2015 Mar; 30(3):451-7. PubMed ID: 25217328
[TBL] [Abstract][Full Text] [Related]
14. Atypical hemolytic uremic syndrome due to factor H autoantibody.
Uslu-Gökceoğlu A; Doğan CS; Comak E; Koyun M; Akman S
Turk J Pediatr; 2013; 55(1):86-9. PubMed ID: 23692839
[TBL] [Abstract][Full Text] [Related]
15. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome.
Moore I; Strain L; Pappworth I; Kavanagh D; Barlow PN; Herbert AP; Schmidt CQ; Staniforth SJ; Holmes LV; Ward R; Morgan L; Goodship TH; Marchbank KJ
Blood; 2010 Jan; 115(2):379-87. PubMed ID: 19861685
[TBL] [Abstract][Full Text] [Related]
16. A favorable 3-year outcome of kidney transplantation in atypical hemolytic uremic syndrome associated with a factor H mutation: case report.
Albertazzi V; Bonucchi D; De Amicis S; Americo C; Ghiandai G; Cappelli G
Transplant Proc; 2010 May; 42(4):1352-4. PubMed ID: 20534299
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of renal transplant in patients with anti-complement factor H antibody-associated hemolytic uremic syndrome.
Khandelwal P; Sinha A; Hari P; Bansal VK; Dinda AK; Bagga A
Pediatr Transplant; 2014 Aug; 18(5):E134-9. PubMed ID: 24814615
[TBL] [Abstract][Full Text] [Related]
18. Anti-Factor H Antibody-Associated Atypical Hemolytic Uremic Syndrome: A Case Report.
Abazi-Emini N; Sahpazova E; Putnik J; Tasic V
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2021 Oct; 42(2):109-115. PubMed ID: 34699711
[No Abstract] [Full Text] [Related]
19. The clinical and laboratory features of Chinese Han anti-factor H autoantibody-associated hemolytic uremic syndrome.
Song D; Liu XR; Chen Z; Xiao HJ; Ding J; Sun SZ; Liu HY; Guo WY; Wang SX; Yu F; Zhao MH;
Pediatr Nephrol; 2017 May; 32(5):811-822. PubMed ID: 28035470
[TBL] [Abstract][Full Text] [Related]
20. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome.
Dragon-Durey MA; Blanc C; Marliot F; Loirat C; Blouin J; Sautes-Fridman C; Fridman WH; Frémeaux-Bacchi V
J Med Genet; 2009 Jul; 46(7):447-50. PubMed ID: 19435718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
